Bavencio

DRUG2 trials

Sponsors

Pfizer, Mirror Biologics, Inc.

Conditions

Metastatic Colorectal CancerRenal Cell Carcinoma

Phase 2

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

WithdrawnNCT06557278

Mirror Biologics, Inc.Metastatic Colorectal Cancer

Start: 2026-11-30End: 2028-11-30Updated: 2025-10-21

Unknown Phase

Axitinib Therapy Management Study

WithdrawnNCT04555603

PfizerRenal Cell Carcinoma

Start: 2020-09-15End: 2021-02-22Updated: 2023-11-21

Related Papers

A phase 2, multicenter, open-label study of AlloStim combined with anti-PD-L1immunotherapy as 4L therapy in patients with MSS/pMMR metastatic colorectal cancer.

Journal of Clinical Oncology2025-01-27